bluuebunny/crossref_metadata_2025_split huggingface dataset:
97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF
Authors: QIN YUEJUAN , ACOSTA FRANCISCA M. , NEPPALA SIVARAM , CORTES TIFFANY M. , STEPANENKO ALLISON , MOODY ALEXANDER , SANCHEZ NOAH D. , BROWN MARISSA , CRUZ MORENO LUIS A. , TRIPLITT CURTIS L. , CLARKE GEOFFREY D. , CERSOSIMO EUGENIO , ESPINOZA SARA E. , DEFRONZO RALPH A. , SOLIS-HERRERA CAROLINA 
Published: June 2023

Background: Cardioprotective benefits of SGLT2 inhibitors (SGLT2i) are well established. However, their effects on cardiopulmonary function measured by CPET in patients with T2D and HFrEF continue to be largely unknown.
Objective: Examine the effects of SGLT2i on cardiopulmonary function measured by cardiopulmonary exercise test (CPET) & 6MWT in patients with T2D & HFrEF.
Methods: Six subjects with T2D with HFrEF (&lt;40%) (Age=59±2.6, BMI=33.3±1.1, A1c=7.1±0.3, EF 28±4%) were randomized to empagliflozin 25mg (SGLT2i) vs. placebo in a 2:1 fashion for 12 weeks. Cardiac MRI, 6MWT, and CPET were performed pre- and post-intervention.
Results: SGLT2i group showed an increase in EF. All subjects reached submaximal cardiovascular effort (RER≤1.10). The Ventilatory Anaerobic Threshold (VT, submaximal index of exercise capacity) showed a significant increase in VT time with SGLT2i (p=0.05). The rest of the parameters trended toward improvement including Ve/VCO2 slope and 6MWT.
Conclusion: Subjects with T2D and HFrEF, treated with an SGLT2i had improved EF, a decrease in the worsening of the Ve/VCO2 slope (a predictor of mortality in HF patients), an increase in 6MWT, and significantly improved VT time (aerobic metabolism) compared to placebo. These findings may represent a novel mechanism of CV protection and warrants further investigation.

Disclosure
Y. Qin: None. C. L. Triplitt: Speaker's Bureau; Novo Nordisk. G. D. Clarke: None. E. Cersosimo: None. S. E. Espinoza: None. R. A. Defronzo: Advisory Panel; AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Novo Nordisk, Research Support; AstraZeneca, Boehringer-Ingelheim, Merck & Co., Inc., Speaker's Bureau; AstraZeneca. C. Solis-herrera: None. F. M. Acosta: None. S. Neppala: None. T. M. Cortes: None. A. Stepanenko: None. A. Moody: None. N. D. Sanchez: None. M. Brown: None. L. A. Cruz moreno: None.

Funding
Doris Duke Charitable Foundation; Voelcker Foundation; National Institutes of Health
971-P: Targeting Personalized Glycemic Response Led to Reduction in Glycemic Variability in Fitterfly CGM Diabetes Digital Therapeutics Program
Authors: VERMA RITIKA , KHADER MOHAMMED A. , LATHIA TEJAL , TANNA SNEHAL R. , PATANGE SONALI A. , SAMUDRA KIRTI , ROHATGI RAGINI M. , CHITALE MANOJ S. , RANADIVE RUCHIRA M. , GUNTUR SAIMALA , SINGAL ARBINDER K. 
Published: June 2023

Background and Aim: Glycemic variability (GV) has shown association with higher risk of diabetes-related complications and increased cardiovascular events in people with T2DM. Personalized glycemic response (PGR) refers to differences in postprandial glycemic response between two people after consumption of the same food. Understanding of PGR after meals can help in improving glycemic control. The study aims at assessing the real-world effectiveness of the PGR based Fitterfly Diabetes CGM program to reduce GV among people with T2DM.
Methods: De-identified data of 220 participants (mean age: 48.8 ± 12.8 years, female: 35.9 % (79/220)), enrolled in the Fitterfly Diabetes CGM program was analyzed. CGM access was provided in the first 14 days of the program. In week-1, the users followed their usual lifestyle where blood sugar readings were correlated with meals and other lifestyle data to understand the PGR of each user. A modified lifestyle plan was introduced in week-2 and was followed till the end of the program. Mean blood glucose (mg/dL), TIR, TAR, TBR, glucose management indicator (GMI), and the percentage coefficient of variation for glucose (CV) were analyzed in week-1 and week-2. All data has been represented as median (IQR).
Results: After 7 days, the median mean blood glucose and TAR significantly reduced by -4.3 (-14.8, 3.3) mg/dL (P&lt;.001) and -2.5 (-11.6, 5.2) % (P&lt;.001) from week-1 baseline of 130.4 (104.4, 169.7) mg/dl and 15.1 (2.8, 36.8) % respectively. The median TIR significantly increased by 1.7 (-2.8, 7.0) % from a baseline of 77.7 (57.2, 89.9) % (P=.001). The median GMI and CV was significantly reduced by -0.1 (-0.3, 0.1) % (P&lt;.001) and -0.7 (-3.4, 1.8) % (P=.005) from baseline of 6.4 (5.8, 7.4) % and 26.9 (22.9, 31.9) % respectively. No significant change was observed in median TBR (P=.40).
Conclusion: The study showed significant improvement in glycemic control and GV after 7 days of PGR-based guidance on the Fitterfly Diabetes CGM program.

Disclosure
R.Verma: Employee; Fitterfly Healthtech Pvt Ltd. S.Guntur: Employee; Fitterfly Health Tech Pvt. Ltd. A.K.Singal: Employee; Fitterfly Healthtech Pvt Ltd. M.A.Khader: Employee; Fitterfly Health Tech Pvt. Ltd. T.Lathia: None. S.R.Tanna: None. S.A.Patange: None. K.Samudra: None. R.M.Rohatgi: None. M.S.Chitale: None. R.M.Ranadive: Employee; Fitterfly Health Tech Pvt. Ltd.

Funding
Fitterfly Healthtech Pvt. Ltd.
974-P: BGM Readings in Range as a Marker of Glycemic Variability in People with Type 2 Diabetes—Interim Analysis from an Ongoing Prospective Study
Authors: MAKKAR BRIJ M. , SOOTA KIRTI , GUPTA VIPUL , SHARMA JUGAL K. , KHURANA GIRISH , CHAWLA RAJEEV 
Published: June 2023

Background: Glycemic variability (GV) is emerging as an independent risk factor for long-term complications. However, measuring GV using CGM is expensive and used sparingly in India. We evaluated BGM readings in-range, above range, and below range (RIR, RAR, RBR) using the OneTouch Verio Flex® (OTVF) BGM with the OneTouch Reveal® (OTR) application to assess GV and its correlation with TIR, TAR and TBR measured using CGM.
Aims and Objectives:1. To evaluate structured BGM as a tool for estimating GV 2. To assess the correlation between BGM-measured RIR, RAR, RBR and the GV parameters reported on AGP using Libre Pro CGM
Materials and Methods: We performed data analysis of 76 completed patients from an ongoing, prospective, multicentre, investigator-initiated study being conducted in New Delhi, India. Persons with T2D on stable treatment (OADs, OADs + Insulin, or Insulin) for ≥ 4 weeks were randomized 1:1 to perform daily 4-point profiles or 7-point profiles using structured BGM readings for 14 days while also wearing blinded CGM using the Libre Pro system. CGM parameters were compared with BGM readings in different ranges measured on the OTR platform.
Results: Most of the PwD performed fewer BGM readings than advised (average readings/day 3.62±1.4). There were strong correlations between daily average glucose, TIR and RIR, TAR and RAR, TBR and RBR (r 0.926, p&lt;0.0001; r 0.805, p&lt;0.00001; r 0.826, p&lt;0.00001; r 0.348, p=0.0092, respectively). Further, there was a significant correlation between 14 days average glucose (158.3mg/dl±56.85 vs 186.13mg/dl±58.9, p=0.0139), TIR vs RIR (66.09%±27.59 vs 52.477%±28.65), TAR vs RAR (30%±29.45 vs 46.95%±28.78, p=0.0029), and TBR vs RBR (3.91%±6.27 vs 0.58%±1.54, p=0.0002).
Conclusion: Structured BGM using OneTouch Verio Flex® paired with the OneTouch Reveal application may be used to assess glycemic variability.

Disclosure
B.M.Makkar: Advisory Panel; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Novartis, Novo Nordisk, Sanofi, Research Support; Lifescan. K.Soota: Research Support; LIFESCAN. V.Gupta: None. J.K.Sharma: None. G.Khurana: None. R.Chawla: None.

Funding
LifeScan
975-P: Clinical and Lifestyle Determinants of Continuous Glucose Monitoring Metrics in Insulin-Treated Patients with Type 2 Diabetes
Authors: YOUNG LEE DA , KIM NAMHO , JUNG INHA , YOUNG PARK SO , HEE YU JI , A SEO JI , PARK SUNG-MIN , HEE KIM NAN 
Published: June 2023

Objective: There was limited evidence to evaluate the association between lifestyle habits and continuous glucose monitoring (CGM) metrics. Thus, we aimed to depict the behavioral and metabolic determinants of CGM metrics in insulin-treated patients with type 2 diabetes (T2DM).
Methods: This is a prospective observational study. We analyzed data from 122 insulin-treated patients with T2DM. Participants wore Dexcom G6 and Fitbit, and diet information was identified for 10 days. Multivariate-adjusted logistic regression analysis was performed for the simultaneous achievement of CGM-based targets, defined by the percentage of time in terms of hyper, hypoglycemia and glycemic variability (GV). Intake of macronutrients and fiber, step counts, sleep, postprandial C-peptide to glucose ratio (PCGR), information about glucose-lowering medications and metabolic factors were added to the analyses. Additionally, we evaluated the impact of the distribution of energy and macronutrient during a day, and snack consumption on CGM metrics.
Results: Logistic regression analysis revealed that female, participants with high PCGR, low HbA1c and daytime step count had a higher probability of achieving all targets based on CGM (odds ratios [95% confidence intervals] which were 0.24 [0.09–0.65], 0.95 [0.9–0.99], 1.34 [1.03–1.25], and 1.15 [1.03–1.29], respectively). And participants who ate snacks showed a shorter period of hyperglycemia and less GV compared to those without.
Conclusions: We confirmed that residual insulin secretion, daytime step count, HbA1c, and women were the most relevant determinants of adequate glycemic control in insulin-treated patients with T2DM. In addition, individuals with snack consumption were exposed to lower times of hyperglycemia and GV.

Disclosure
D.Lee: None. N.Kim: None. I.Jung: None. S.Park: None. J.Yu: None. J.Seo: None. S.Park: None. N.Kim: None.

Funding
National Research Foundation of Korea (2019M3E5D3073102, 2019R1H1A2039682, 2020R1I1A1A01071665); National IT Industry Promotion Agency (S0252-21-1001)
977-P: Continuous Glucose Monitoring in the Early Post–Lung Transplantation Period
Authors: MUNOZ PENA JUAN M. , RASMUSSEN HANNAH , SALLOUM RAMZI G. , CHONG LEONG MAN , ALGARRA KIMBERLY A. 
Published: June 2023

Objective: Post-Transplant Diabetes Mellitus (PTDM) occurs in an estimated 20-40% of lung transplantation within five years, and hyperglycemia adversely affects outcomes, including rejection, infection, cardiovascular events, and mortality. Whereas continuous glucose monitoring (CGM) is common in patients with type 1 and type 2 diabetes mellitus, there is a significant knowledge gap in its application to PTDM. The objective of this study was to evaluate the performance of CGM in detecting hypoglycemia and hyperglycemia in the early post-lung transplantation period, compared with self-monitoring blood glucose.
Research and Design Methods: We conducted a prospective pilot study with patients aged 18-75 who underwent lung transplantation and had hyperglycemia managed with insulin. Enrolled patients wore a blinded CGM at discharge and self-monitored glucose levels at home for 10 days. Data were summarized according to the following categories and compared across both tests using the paired t-test: % time in range (70-180 mg/dl); % high (181-250 mg/dl); % very high (&gt;250 mg/dl); % low (50-69 mg/dl); % very low (&lt;50 mg/dl).
Results: The sample included 15 patients (mean age 58.6 years; 53.3% men; 73.3% with pre-transplantation diabetes). There was a significantly higher rate of detection for hyperglycemia with CGM use vs. self-monitored blood glucose. For the “% very high” group, the mean difference was 7.12, (95% confidence interval [CI], 1.8-12.4), and for the “% high” group, the mean difference was 11.1, (95% CI, 3.5-18.8), and for the combined group, “% high and % very high”, the mean difference was 18.3, (95% CI: 7.37-29.24). There was no statistically significant difference for the “% low and % very low” groups.
Conclusions: CGM demonstrated a higher rate of detection for hyperglycemia compared to self-monitoring blood glucose. The mean difference for hypoglycemia detection was not significant. Larger studies are required to provide statistically meaningful conclusions about CGM in PTDM.

Disclosure
J.M.Munoz pena: None. H.Rasmussen: None. R.G.Salloum: None. M.Leong: None. K.A.Algarra: None.

Funding
Dexcom, Inc. (MM130159)
98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF
Authors: QIN YUEJUAN , SANCHEZ NOAH D. , MOODY ALEXANDER , ACOSTA FRANCISCA M. , NEPPALA SIVARAM , BROWN MARISSA , HONKA HENRI , CRUZ MORENO LUIS A. , TRIPLITT CURTIS L. , CLARKE GEOFFREY D. , CERSOSIMO EUGENIO , DEFRONZO RALPH A. , SOLIS-HERRERA CAROLINA 
Published: June 2023

Background: The CV benefits of SGLT2i are well established. However, how skeletal muscle (SkM) bioenergetics respond to SGLT2i in T2D and HFrEF remains largely unknown.
Objective: To explore the effects of empagliflozin on SkM bioenergetics (phosphorus metabolites & myocellular lipid content) at rest and post-exercise (31P & 1H MRS) and cardiac function (MRI). Methods: Subjects with T2D & HFrEF (&lt;40%) (n=6) were randomized 2:1 to empagliflozin 25mg (SGLT2i) or placebo for 12 wks (Age=59±2.6, BMI=33.3±1.1, A1c=7.1±0.3, EF 28±4%). A cardiac MRI, & static/dynamic 31P & 1H SkM by MRS, were performed before & after treatment.
Results: In the empagliflozin group, SkM 31P MRS at rest, showed decrease in phosphodiesterase [PDE]. 31P MRS post-exercise, showed significant improvement in Phosphocreatinine (PCr) recovery, expressed by the K value. 1H MRS showed a reduction of saturated intramyocellular lipids (IMCL-CH2:CH3 ratio).
Conclusion: Empagliflozin in subjects with T2D and HFrEF had beneficial effects in SkM energy utilization and muscle recovery post-exercise as determined by a decrease in PDE and increase in K value. Additionally, empagliflozin decreased saturated IMCL, which could be expected to improve mitochondrial function and energy utilization. If similar findings were to occur in cardiac muscle, this could provide a novel mechanism for the beneficial CV effects of SGLT2i.

Disclosure
Y. Qin: None. N. D. Sanchez: None. A. Moody: None. F. M. Acosta: None. S. Neppala: None. M. Brown: None. H. Honka: None. L. A. Cruz Moreno: None. C. L. Triplitt: Speaker's Bureau; Novo Nordisk. G. D. Clarke: None. E. Cersosimo: None. R. A. DeFronzo: Speaker's Bureau; AstraZeneca. Advisory Panel; AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Novo Nordisk. Research Support; AstraZeneca, Boehringer-Ingelheim, Merck & Co., Inc. C. Solis-Herrera: None.

Funding
Doris Duke Charitable Foundation; Voelcker Foundation; National Institutes of Health
98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial
Authors: ISHAY YUVAL , NEUTEL JOEL M. , KOLBEN YOTAM , GELMAN RAM , SNEH ARBIB ORLY , LOPEZ OLIVER , SOTOLONGO ROBERTO , ILAN YARON , KIDRON MIRIAM 
Published: June 2023

NAFLD is the most common liver disorder in the USA. NASH is an advanced form of NAFLD and a leading cause of end-stage liver disease and indication for liver transplantation. Insulin resistance and inflammation underlie the pathogenesis of the disease. This double-blind, randomized, placebo-controlled, multicenter study aimed to determine the effect of oral insulin in patients with NASH and T2DM. Patients were treated twice daily for 12 weeks with an 8 mg insulin (n=21) or placebo (n=11) capsule. Safety was monitored throughout the study. At screening and after 12 weeks of treatment, liver fat content was measured by MRI-PDFF and liver fibrosis and steatosis levels by FibroScan®. No severe drug-related adverse events were reported during the study. After 12 weeks of treatment, mean percent reductions in whole-liver (-11.2±22.8% vs. -6.5±15.3%, respectively) and liver segment 3 (-11.7±21.1% vs. +0.1±17.3%, respectively) fat content were higher in the insulin as compared to the placebo arm. Patients receiving insulin showed a median -1.1 kPa and -21.0 dB/m reduction from baseline fibrosis and steatosis levels, respectively. In comparison, placebo-treated patients showed median increases of 0.3 kPa and 13.0 dB/m, respectively. At Week 12, HbA1c levels decreased by a mean -0.27±1.3% in the oral insulin cohort and increased by a mean 0.23±0.73% in the placebo cohort. Mean percent changes from baseline ALT and AST levels were -0.1±30.4% and -0.8±28.6%, respectively, in the oral insulin arm and 3.0±26.7% and 13.4±46.6%, respectively, in the placebo arm. Over the treatment period, mean total cholesterol, HDL, LDL, and triglycerides levels were consistently lower than baseline in the active arm and higher than baseline in the placebo arm. The results of this feasibility study support the safety and potential therapeutic effect of orally delivered insulin on liver fibrosis, fat accumulation, and inflammatory processes.

Disclosure
Y.Ishay: None. J.M.Neutel: None. Y.Kolben: None. R.Gelman: None. O.Sneh arbib: None. O.Lopez: None. R.Sotolongo: None. Y.Ilan: None. M.Kidron: Employee; Oramed Pharmaceuticals.
986-P: Near-Infrared Device for Screening of Diabetes—ANODE02 Study
Authors: XAVIER COS FRANCESC , LAZARO-PACHECO DANIELA , SALTER JOHN E. , PALDANIUS PAIVI M. 
Published: June 2023

Background: Currently, screening for diabetes mellitus (DM) can be complex, inefficient and often resource-intensive with invasive sampling. Affordable screening tools with high specificity will be essential for smart allocation of limited healthcare resources for those in need of further diagnostics.
Materials and methods: We explored the accuracy and safety of a novel compact miniaturized near-infrared (NIR) full-spectrum spectroscopy device intended for DM screening. Assessments of up to 30 NIR spectra per each middle fingernail and hand, in a cohort of people living with (n=50) or without (n=50) DM focused on detection of dichotomised DM status (&lt; HbA1c 48 mmol/mol or 6.5% ≥) and specificity (%) based chemometrics outcomes, in assessment of glycated nail keratin versus an HbA1c point-of-care assay as control.
Results: Demographics of a community primary care centre-based cohort (n=100) are presented in Table. Overall, no adverse NIR-device-related events were being reported for any of the over 6000 spectral measurements. Based on the best chemometrics model, the NIR-device demonstrated a specificity of 98.5% (95%CI 95.5 - 100.0) and 88.9% (80.5 - 97.3) at 48 and 42 mmol/mol cut-off levels, respectively, in detection of those without DM.
Conclusions: Our preliminary results are indicative of high specificity and safe implementation of non-invasive NIR technology with potential for early detection and management of increasing DM risk.

Disclosure
F.Cos: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Abbott Diagnostics, Lilly, Novo Nordisk, Consultant; Glyconics Ltd, Menarini Group, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly. D.Lazaro-pacheco: Consultant; Glyconics Ltd. J.E.Salter: None. P.M.Paldanius: Consultant; Glyconics Ltd, Speaker's Bureau; Novartis.

Funding
Glyconics
99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure
Authors: SOLIS-HERRERA CAROLINA , QIN YUEJUAN , HONKA HENRI , ACOSTA FRANCISCA M. , MOODY ALEXANDER , CHAVEZ ALBERTO , TRIPLITT CURTIS L. , CLARKE GEOFFREY D. , CERSOSIMO EUGENIO , DEFRONZO RALPH A. 
Published: June 2023

Background: SGLT2 inhibitors have been shown to provide CV benefits in HFpEF and HFrEF patients with and without diabetes. The underlying mechanisms continue being explored.
Objective: To examine the effect of hyperketonemia on myocardial blood flow (MBF) in patients with HF and T2DM.
Methods: Subjects with T2DM and HF (EF &lt;50%) received a 6-hr BOHB infusion or a HCO3 infusion (control). A cardiac MRI and a PET study with 18FDG and 15O water were performed before and after the infusion.
Results: Twelve Subjects were studied (Age=60; BMI=32 kg/m2; A1c = 7.7%). Plasma ketone levels reached 1.6±0.2mmol/L. MBF significantly increased in six subjects (“responders” 1.05±0.13 to 1.38±0.17, p = 0.003) and decrease in six subjects (“non-responders” 1.44±0.07 to 0.95±0.08, p = 0.007). With multivariable analysis, only baseline EF was shown to significantly correlate with the increase in MBF.
Conclusion: These findings suggest that patients with a higher baseline EF might be more responsive to ketones and be able to increase MBF as an additional mechanism of CV improvement. These novel results shed new light on the potential effect of ketones in different populations of patients with HF and needs to be further explored.

Disclosure
C. Solis-Herrera: None. Y. Qin: None. H. Honka: None. F. M. Acosta: None. A. Moody: None. A. Chavez: None. C. L. Triplitt: Speaker's Bureau; Novo Nordisk. G. D. Clarke: None. E. Cersosimo: None. R. A. DeFronzo: Speaker's Bureau; AstraZeneca. Advisory Panel; AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Novo Nordisk. Research Support; AstraZeneca, Boehringer-Ingelheim, Merck & Co., Inc.

Funding
Max and Minnie Tomerlin Voelcker Fund; Merck & Co., Inc.
Påstandsspill som et verktøy i undervisning om bærekraftig utvikling i barnehagelærerutdanningen
Authors: Botnen Synnøve Smebye , Sandbakken Mari 
Published: June 2023

I lys av klimaendringer og tap av natur, blir det å jobbe målrettet med bærekraftig utvikling og utforsking av naturen stadig viktigere for barnehagefeltet. For barnehagelærerutdanningen blir det da nødvending å utvikle undervisning som fremmer både kunnskaper, holdninger og refleksjoner knyttet til natur og bærekraftig utvikling. I denne artikkelen vil vi ta for oss et verktøy for å måle naturtilknytning: nature relatedness scale. Vi ønsker å undersøke og diskutere hvordan påstander fra verktøyet kan fremme refleksjon rundt praksiser, holdninger og kunnskaper relatert til bærekraftig utvikling i barnehagen. Vi har brukt påstandene fra skalaen til å utvikle et påstandsspill som har blitt testet ut av studenter fra arbeidsplassbasert barnehagelærerutdanning. Empirien i studien består av observasjon og dokumentasjon av studentenes dialoger under gjennomføring av spillet, og vi har spurt studentene om hvordan de opplever relevansen av dette for barnehagelæreryrket. Gjennom diskusjonen mellom studentene i påstandsspillet kom barnehageperspektivet fram under de fleste påstandene. Studentene rapporterte at de ble mer bevisste på sine holdninger og handlinger rundt arbeid med bærekraftig utvikling i barnehagen, og vi mener dette derfor kan være et nyttig verktøy i utdanning for bærekraftig utvikling.
ENGLISH ABSTRACT
Statement game as a tool in education for sustainable development in early childhood teacher education
Considering climate change and loss of nature, working with sustainable development and exploration of nature becomes ever more important in the field of early childhood education. It is therefore necessary to develop teaching practices that highlight both knowledge, attitudes, and reflections related to nature and sustainable development in early childhood teacher education. In this paper, we will explore how statements from a scale called “nature relatedness scale” can stimulate reflections on practices, attitudes and knowledge related to sustainable development in early childhood education. We have used the statements to develop a statement game and tested the game with students in work-based early childhood teacher education. We observed and documented students’ dialogues during the statement game and asked them if they found this relevant for their profession. During the discussions of most of the statements, early childhood perspectives emerged. The students stated that the discussions raised their awareness of working with sustainable development in early childhood education, and we therefore find that this can be a useful tool in education for sustainable development.